Norges Bank’s Voyager Therapeutics VYGR Stock Holding History

Norges Bank’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-90,400	Closed	-$426K	–	2259
2021 Q1	$426K	Buy	+90,400	New	+$616K	﹤0.01%	2095

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Norges Bank's VYGR Position: Q2 2021 in Review

Norges Bank sold out of Voyager Therapeutics (VYGR) in Q2 2021, closing a stake of 90,400 shares — an estimated $426K sold.

Norges Bank first reported a position in VYGR in Q1 2021 and held it in 1 quarter. The position peaked at $426K in Q1 2021. 78 funds tracked by Wall St. Rank hold VYGR as of Q2 2021.

Norges Bank reported no remaining Voyager Therapeutics position as of Q2 2021 after selling out during the quarter.
Norges Bank sold 90,400 Voyager Therapeutics shares in Q2 2021, an estimated $426K.
Norges Bank first reported a position in Voyager Therapeutics in Q1 2021 and held it in 1 quarter.
Norges Bank's Voyager Therapeutics position peaked at $426K in Q1 2021.
78 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2021.

Based on Norges Bank's 13F filing for Q2 2021, filed 10 Aug 2021.